24.39
0.49 (2.05%)
| Previous Close | 23.90 |
| Open | 24.07 |
| Volume | 1,142,988 |
| Avg. Volume (3M) | 2,017,732 |
| Market Cap | 4,126,344,704 |
| Price / Earnings (TTM) | 15.74 |
| Price / Earnings (Forward) | 38.46 |
| Price / Sales | 4.00 |
| Price / Book | 4.58 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | 22.97% |
| Operating Margin (TTM) | 7.90% |
| Diluted EPS (TTM) | 1.37 |
| Quarterly Revenue Growth (YOY) | 18.70% |
| Quarterly Earnings Growth (YOY) | 14.70% |
| Total Debt/Equity (MRQ) | 7.32% |
| Current Ratio (MRQ) | 2.88 |
| Operating Cash Flow (TTM) | 148.96 M |
| Levered Free Cash Flow (TTM) | 19.27 M |
| Return on Assets (TTM) | 5.56% |
| Return on Equity (TTM) | 37.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | ACADIA Pharmaceuticals Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.57% |
| % Held by Institutions | 104.46% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 39.00 (UBS, 59.90%) | Buy |
| 39.00 (TD Cowen, 59.90%) | Buy | |
| Median | 32.00 (31.20%) | |
| Low | 29.00 (Mizuho, 18.90%) | Hold |
| 29.00 (Needham, 18.90%) | Buy | |
| Average | 33.14 (35.88%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 23.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 02 Dec 2025 | 29.00 (18.90%) | Hold | 25.43 |
| JP Morgan | 17 Nov 2025 | 31.00 (27.10%) | Buy | 24.01 |
| 29 Sep 2025 | 33.00 (35.30%) | Buy | 21.32 | |
| Needham | 06 Nov 2025 | 29.00 (18.90%) | Buy | 21.65 |
| 24 Sep 2025 | 28.00 (14.80%) | Buy | 21.26 | |
| RBC Capital | 06 Nov 2025 | 32.00 (31.20%) | Buy | 21.65 |
| Citigroup | 21 Oct 2025 | 33.00 (35.30%) | Buy | 21.27 |
| TD Cowen | 11 Sep 2025 | 39.00 (59.90%) | Buy | 24.20 |
| UBS | 09 Sep 2025 | 39.00 (59.90%) | Buy | 24.84 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |